NICE change of heart for BMS/AZ's Forxiga
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has decided after all to recommend Bristol-Myers Squibb/AstraZeneca's diabetes type 2 drug Forxiga (dapagliflozin) for use on the National Health Service. Earlier this year the institute was not so sure.